Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “This investigational drug is a transdermal patch indicated to treat allergic conjunctivitis. Application is intended for overnight wear between 8-10 hours.”In the company’s words, NCT00836485 on ClinicalTrials.gov
- Tested for
- Allergic Conjunctivitis
- Main trialPhase 2
- “This is a phase 2 study that will consist of 4 visits over a 5 week period. Drug will be evaluated using the conjunctival allergen challenge model of allergic conjunctivitis.”In the company’s words, NCT00836485 on ClinicalTrials.gov
Other drugs for Allergic Conjunctivitis
- CenegerminDompé Farmaceutici S.p.A · Phase 3
- FreneslerbartRegeneron · Phase 3
- MevonlerbartRegeneron · Phase 3
- REGN1908-1909Regeneron · Phase 3
- T1695Laboratoires Thea · Phase 2
- TL-925Telios Pharma, Inc. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | Mar 2009 | Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026